FlashForward™ Consortium

FLASH therapy is an experimental treatment modality delivering radiotherapy at ultra-high dose rates to treatment volumes in typically <1 second.

Flash Forward Ultra High Dose Rate Chart

FLASH therapy could be one of the most significant advancements in cancer treatment in decades.

FLASH Therapy is an experimental treatment modality delivering radiotherapy at ultra-high dose rates to treatment volumes in typically <1 second. Compared to conventional therapy, preclinical studies in mice have shown equivalent or better tumour control, reduced normal tissue toxicity, and immunological advantages.

Varian’s FlashForward™ Consortium is formed from institutions around the world to establish preclinical study designs, develop technical solutions, and share research protocols to help advance the science and clinical translation of FLASH therapy.

Consortium members

  • CHUV Lausanne University Hospital
  • Cincinnati Children's/UC Health Proton Therapy Centre
  • Danish Centre for Particle Therapy
  • Emory Proton Therapy Centre
  • Hefei Ion Medical Centre
  • Holland Proton Therapy Centre
  • New York Proton Centre
  • Oslo University Proton Therapy Centre
  • Paul Scherrer Institute
  • Penn Medicine
  • Shandong Proton Therapy Centre
  • Singapore Proton Therapy Centre
  • South Florida Proton Therapy Institute
  • St. Petersburg Proton Therapy Centre
  • The Christie Proton Therapy Centre
  • University College London
  • University of Alabama at Birmingham
  • University of Maryland Department of Radiation Oncology
  • University of Miami Sylvester Comprehensive Cancer Centre
  • VU University Medical Centre Amsterdam

World’s First FLASH Clinical Trial

Feasibility Study of FLASH Proton Radiotherapy for the Treatment of Symptomatic Bone Metastases (FAST-01)

FAST-01 is a first-in-human clinical trial evaluating the feasibility and safety of FLASH radiotherapy in patients with painful bone metastases of the extremities. A standard palliative dose fractionation regimen of 8 Gy in a single fraction is delivered with a 250MeV transmission proton beam at FLASH dose rates. The FAST-01 study is actively enrolling eligible patients at least 18 years of age at Cincinnati Children’s Hospital Medical Centre (PI: Dr. J. Breneman). The design of the follow-up trial FAST-02 is underway.

Study details:

  • Patients with Bone metastases of the extremities
  • Enrolment for the study is open now
  • Study uses a modified ProBeam for the IDE
  • In partnership with Cincinnati Children’s/University of Cincinnati Medical Centre, Proton Therapy Centre

For additional information, please see the Feasibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases.

Trials using FLASH radiotherapy for lung cancer and other malignancies are currently being developed. Using FLASH treatment for these cancers could deliver higher cancer-killing doses without causing inordinate side effects, which would be a real advance.

- Dr. John Breneman
Medical Director at Cincinnati Children’s Hospital Medical Centre UC Health Proton Therapy Centre

FLASH therapy has the potential to be practice-changing and drastically improve the experience of cancer care for a new generation of patients. The launch of the first FLASH clinical trial, a project that has come to fruition after years of intensive study, is an important milestone in the progress of radiation therapy.

- Dr. Charles B. Simone, II
FACRO, Chief Medical Officer at New York Proton Centre

Complementing FlashForward


 

ProBeam 360

ProBeam 360

Next-generation proton therapy with a smaller footprint.

Learn more >

Interested in knowing more?

Contact us to learn more about the FlashForward Consortium and FLASH therapy.